Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults
Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults
Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults
Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus
Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
In January 2020, we withdrew this guidance to allow for further consultation with stakeholders.